• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估瑞德西韦(GS-5734)在猫血浆和全血中的稳定性以及向GS-441524的转化。

Assessing stability of remdesivir (GS-5734) and conversion to GS-441524 in feline plasma and whole blood.

作者信息

Coggins Sally J, Kimble Benjamin, Malik Richard, Thompson Mary F, Norris Jacqueline M, Govendir Merran

机构信息

Sydney School of Veterinary Science, The University of Sydney, Camperdown, Australia.

Centre for Veterinary Education, The University of Sydney, Camperdown, Australia.

出版信息

Vet Q. 2024 Dec;44(1):1-9. doi: 10.1080/01652176.2024.2305731. Epub 2024 Jan 30.

DOI:10.1080/01652176.2024.2305731
PMID:38288972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10829815/
Abstract

Feline infectious peritonitis (FIP) is a potentially fatal coronavirus-driven disease of cats. Treatment with nucleoside analogue GS-441524 and or prodrug remdesivir (RDV) have produced remission in both experimentally induced and naturally occurring FIP, yet information regarding metabolism of RDV into GS-441524 in cats is scarce. This study assessed possible phase I metabolism of RDV in cats, utilising an  feline microsome model with in vitro t and  Cl calculated using the substrate depletion method. A previously validated high-performance liquid chromatography (HPLC) fluorescence method was utilised for detection and analysis of RDV and GS-441524. Qualitative yield of RDV and intermediate metabolite GS-441524 were determined following microsome incubation, then compared to whole blood and plasma incubations.  microsome incubation resulted in rapid depletion of RDV, though it did not appear to resemble a conventional phase I-dependent reaction in cats, as it is in humans and dogs. Depletion of RDV into GS-441524 was demonstrated in whole blood , suggesting cats convert RDV to GS-441524, likely via blood esterases, as observed in mice and rats. RDV metabolism is unlikely to be impacted by impaired liver function in cats. Furthermore, as RDV depletes within minutes, whereas GS-441524 is very stable, whole blood or plasma GS-441524 concentrations, rather than plasma RDV concentrations, are more appropriate for therapeutic drug monitoring (TDM) in cats receiving RDV.

摘要

猫传染性腹膜炎(FIP)是一种由冠状病毒引起的、对猫有潜在致命性的疾病。用核苷类似物GS-441524和/或前药瑞德西韦(RDV)治疗已使实验诱导型和自然发生型FIP均出现缓解,但关于猫体内RDV代谢为GS-441524的信息却很少。本研究利用猫微粒体模型,采用底物消耗法计算体外t和Cl,评估了猫体内RDV可能的I相代谢。采用先前验证的高效液相色谱(HPLC)荧光法对RDV和GS-441524进行检测和分析。在微粒体孵育后测定RDV和中间代谢产物GS-441524的定性产率,然后与全血和血浆孵育结果进行比较。微粒体孵育导致RDV迅速消耗,不过在猫身上它似乎并不类似于人类和狗身上的传统I相依赖性反应。在全血中证实了RDV向GS-441524的消耗,这表明猫可能像在小鼠和大鼠中观察到的那样,通过血液酯酶将RDV转化为GS-441524。猫的RDV代谢不太可能受到肝功能受损的影响。此外,由于RDV在几分钟内就会耗尽,而GS-441524非常稳定,对于接受RDV治疗的猫,全血或血浆中GS-441524的浓度比血浆中RDV的浓度更适合用于治疗药物监测(TDM)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/54ae220c9ae9/TVEQ_A_2305731_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/a05c81cd3547/TVEQ_A_2305731_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/5877824c74b9/TVEQ_A_2305731_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/54ae220c9ae9/TVEQ_A_2305731_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/a05c81cd3547/TVEQ_A_2305731_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/5877824c74b9/TVEQ_A_2305731_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c30/10829815/54ae220c9ae9/TVEQ_A_2305731_F0003_C.jpg

相似文献

1
Assessing stability of remdesivir (GS-5734) and conversion to GS-441524 in feline plasma and whole blood.评估瑞德西韦(GS-5734)在猫血浆和全血中的稳定性以及向GS-441524的转化。
Vet Q. 2024 Dec;44(1):1-9. doi: 10.1080/01652176.2024.2305731. Epub 2024 Jan 30.
2
An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats.一种优化的生物测定法,用于筛选针对猫传染性腹膜炎病毒的联合抗病毒化合物,同时对猫体内 GS-441524、瑞德西韦和莫那比拉韦的药代动力学进行分析。
Viruses. 2022 Nov 1;14(11):2429. doi: 10.3390/v14112429.
3
Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022).回顾性研究及合法兽医配制瑞德西韦和 GS-441524 制剂治疗 307 例猫传染性腹膜炎的结果(2020-2022 年)。
J Feline Med Surg. 2023 Sep;25(9):1098612X231194460. doi: 10.1177/1098612X231194460.
4
Quantification of GS-441524 concentration in feline plasma using high performance liquid chromatography with fluorescence detection.采用高效液相色谱荧光检测法测定猫血浆中 GS-441524 浓度。
Vet Q. 2023 Dec;43(1):1-9. doi: 10.1080/01652176.2023.2246553.
5
Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524.32 只患有渗出性或非渗出性猫传染性腹膜炎的猫接受瑞德西韦和 GS-441524 的联合治疗。
J Vet Intern Med. 2023 Sep-Oct;37(5):1784-1793. doi: 10.1111/jvim.16804. Epub 2023 Jul 4.
6
Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.使用经肠胃外给予瑞德西韦治疗,以及是否转为经口给予 GS-441524 治疗猫传染性腹膜炎的效果。
J Vet Intern Med. 2023 Sep-Oct;37(5):1772-1783. doi: 10.1111/jvim.16803. Epub 2023 Jul 13.
7
Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study.口服瑞德西韦对比 GS-441524 治疗自然发生湿性猫传染性腹膜炎的疗效:一项双盲、非劣效性研究。
Viruses. 2023 Aug 1;15(8):1680. doi: 10.3390/v15081680.
8
The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies.核苷类似物 GS-441524 能在组织培养和实验猫感染研究中强烈抑制猫传染性腹膜炎(FIP)病毒。
Vet Microbiol. 2018 Jun;219:226-233. doi: 10.1016/j.vetmic.2018.04.026. Epub 2018 Apr 22.
9
First analytical confirmation of drug-induced crystal nephropathy in felines caused by GS-441524, the active metabolite of Remdesivir.首次分析确认瑞德西韦的活性代谢物 GS-441524 在猫科动物中引起的药物性结晶肾病。
J Pharm Biomed Anal. 2024 Sep 1;247:116248. doi: 10.1016/j.jpba.2024.116248. Epub 2024 May 22.
10
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.瑞德西韦的药代动力学、药效学和药物相互作用特征:一种 SARS-CoV-2 复制抑制剂。
Clin Pharmacokinet. 2021 May;60(5):569-583. doi: 10.1007/s40262-021-00984-5. Epub 2021 Mar 30.

引用本文的文献

1
Efficacy of oral remdesivir in treating feline infectious peritonitis: a prospective observational study of 29 cats.口服瑞德西韦治疗猫传染性腹膜炎的疗效:29只猫的前瞻性观察研究
J Feline Med Surg. 2025 May;27(5):1098612X251335189. doi: 10.1177/1098612X251335189. Epub 2025 May 27.
2
Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021-2024).6只猫静脉注射瑞德西韦后GS-441524的药代动力学及猫传染性腹膜炎治疗期间治疗药物监测结果:22例(2021 - 2024年)
J Small Anim Pract. 2025 Jul;66(7):495-506. doi: 10.1111/jsap.13849. Epub 2025 Mar 17.

本文引用的文献

1
Quantification of GS-441524 concentration in feline plasma using high performance liquid chromatography with fluorescence detection.采用高效液相色谱荧光检测法测定猫血浆中 GS-441524 浓度。
Vet Q. 2023 Dec;43(1):1-9. doi: 10.1080/01652176.2023.2246553.
2
Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.使用经肠胃外给予瑞德西韦治疗,以及是否转为经口给予 GS-441524 治疗猫传染性腹膜炎的效果。
J Vet Intern Med. 2023 Sep-Oct;37(5):1772-1783. doi: 10.1111/jvim.16803. Epub 2023 Jul 13.
3
Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524.
32 只患有渗出性或非渗出性猫传染性腹膜炎的猫接受瑞德西韦和 GS-441524 的联合治疗。
J Vet Intern Med. 2023 Sep-Oct;37(5):1784-1793. doi: 10.1111/jvim.16804. Epub 2023 Jul 4.
4
Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524.用含有 GS-441524 的口服多组分药物治疗猫传染性腹膜炎。
Viruses. 2021 Nov 5;13(11):2228. doi: 10.3390/v13112228.
5
Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis.未经许可的类GS-441524抗病毒疗法可有效用于猫传染性腹膜炎的居家治疗。
Animals (Basel). 2021 Jul 30;11(8):2257. doi: 10.3390/ani11082257.
6
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.瑞德西韦的吸收、分布、代谢、排泄及药代动力学特性:其药物相互作用潜力
Pharmaceuticals (Basel). 2021 Jul 8;14(7):655. doi: 10.3390/ph14070655.
7
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.瑞德西韦为何失败:临床前假设高估了瑞德西韦对新冠病毒和埃博拉病毒的临床疗效。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0111721. doi: 10.1128/AAC.01117-21. Epub 2021 Jul 12.
8
Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An and DMPK assessment.瑞德西韦及其母体核苷GS-441524能否成为潜在的口服药物?一项吸收、分布、代谢和排泄及药物代谢动力学评估。
Acta Pharm Sin B. 2021 Jun;11(6):1607-1616. doi: 10.1016/j.apsb.2021.03.028. Epub 2021 Mar 22.
9
Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.一名需要持续静静脉血液透析的重症新冠肺炎患者体内瑞德西韦代谢物的血浆浓度。
Eur J Clin Pharmacol. 2021 Oct;77(10):1583-1585. doi: 10.1007/s00228-021-03128-7. Epub 2021 May 12.
10
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.瑞德西韦代谢产物 GS-441524 有效抑制 SARS-CoV-2 感染的小鼠模型。
J Med Chem. 2022 Feb 24;65(4):2785-2793. doi: 10.1021/acs.jmedchem.0c01929. Epub 2021 Feb 1.